New lung cancer classification predicts recurrence

This article originally appeared here.
New Lung Cancer Classification IDs Recurrence After Resection
New Lung Cancer Classification IDs Recurrence After Resection

(HealthDay News) -- The new International Association for the Study of Lung Cancer (IASLC), American Thoracic Society (ATS), and European Respiratory Society (ERS) lung adenocarcinoma classification can be used to predict recurrence after limited resection, according to a study published online Aug. 7 in the Journal of the National Cancer Institute.

Jun-ichi Nitadori, M.D., Ph.D., from the Memorial Sloan-Kettering Cancer Center in New York City, and colleagues analyzed the prognostic significance of the IASLC/ATS/ERS classification using data from 734 consecutive patients who underwent lung resection (LR; 258 patients) or lobectomy (LO; 476 patients) for small lung adenocarcinoma between 1995 and 2009.

The researchers found that, in the LR group, but not the LO group, micropapillary (MIP) component of 5 percent or greater versus less than 5 percent correlated with a significantly increased risk of recurrence (LR: five-year cumulative incidence of recurrence, 34.2 versus 12.4 percent; P < 0.001). For patients in the LR group with tumors with an MIP component of 5 percent of greater, 63.4 percent of recurrences were locoregional. When the surgical margin was less than 1 cm, but not when it was 1 cm or greater, an MIP component of 5 percent or greater correlated with a significantly increased risk of local recurrence (five-year cumulative incidence of recurrence, 32.0 percent for MIP ≥5 percent versus 7.6 percent for MIP <5 percent; P = 0.007).

"Application of the IASLC/ATS/ERS classification identifies the presence of an MIP component of 5 percent or greater as independently associated with the risk of recurrence in patients treated with LR," the authors write.

Abstract
Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)

Loading links....
You must be a registered member of ONA to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs